Metal-Ligand Equilibria in Solution: A Generalized Approach

892-89

Binary Cu(II) Complexes with 7-Hydroxy-8-phenylazonaphthalene-1,3-disulphonate (Orange G) & Mixed Ligand Complexes Involving 2,2-Dipyridyl & Nitrilotriacetic Acid as Primary Ligands

900-90

Mixed Ligand Chelates of Cu(II), Zn(II), Ni(II) & Co(II) with Nitrilotriacetic Acid as the Primary Ligand & 3,5-Dinitro- & 3,5-Dibromo-salicylic Acids as Secondary Ligands

633-63

Simultaneous Titrimetric Determination of La(lII) & Ce(IV) in Their Mixtures

518-52

Potential benefits of Glycyrrhiza glabra (Liquorice) herb, its chemical make-up and significance in safeguarding poultry health: Current scientific knowledge

Positive results have been seen when bioactive components from herbal plants are added to poultry diets. Efficacy in feeding, digestion of nutrients, antioxidant health, immunological indices, and other factors can all be improved with the help of these additives, which in turn increases growth rates and improves poultry welfare. Several researchers have used sophisticated herbal formulae that included Glycyrrhiza glabra (Liquorice) as an ingredient. Epidemic illnesses, mainly in the respiratory, digestive, and immunological systems, pose the greatest threat to the poultry business. Flavonoids and glycyrrhizin are two of the bioactive compounds in Liquorice. The roots of this plant contain glycyrrhizin at concentrations of 1-9%, which has numerous pharmacological benefits, including anti-infectious, antioxidant, antiviral, and anti-inflammatory properties. Liquorice extracts are helpful in the treatment of multiple common illnesses. These include problems with the liver, the lungs, and the immunological system. Adding Liquorice to chicken diets improves their productivity in several ways, including fostering organ growth and stimulating digestion and appetite. Liquorice has many beneficial effects on birds, including helping them grow larger bodies, cleansing their systems, and protecting them from free radicals, bacteria, and inflammation. In this article, we'll look at the chemical make-up of liquorice herb, its role in protecting poultry health, and its recent applications and benefits

High Precision Measurements of Interstellar Dispersion Measure with the upgraded GMRT

Pulsar radio emission undergoes dispersion due to the presence of free electrons in the interstellar medium (ISM). The dispersive delay in the arrival time of pulsar signal changes over time due to the varying ISM electron column density along the line of sight. Correcting for this delay accurately is crucial for the detection of nanohertz gravitational waves using Pulsar Timing Arrays. In this work, we present in-band and inter-band DM estimates of four pulsars observed with uGMRT over the timescale of a year using two different template alignment methods. The DMs obtained using both these methods show only subtle differences for PSR 1713+0747 and J1909$-$3744. A considerable offset is seen in the DM of PSR J1939+2134 and J2145$-$0750 between the two methods. This could be due to the presence of scattering in the former and profile evolution in the latter. We find that both methods are useful but could have a systematic offset between the DMs obtained. Irrespective of the template alignment methods followed, the precision on the DMs obtained is about $10^{-3}$ pc cm$^{-3}$ using only BAND3 and $10^{-4}$ pc cm$^{-3}$ after combining data from BAND3 and BAND5 of the uGMRT. In a particular result, we have detected a DM excess of about $5\times10^{-3}$ pc cm$^{-3}$ on 24 February 2019 for PSR J2145$-$0750. This excess appears to be due to the interaction region created by fast solar wind from a coronal hole and a coronal mass ejection (CME) observed from the Sun on that epoch. A detailed analysis of this interesting event is presented.Comment: 11 pages, 6 figures, 2 tables. Accepted by A&

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that cause millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients’ disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient’s physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.All the authors are highly grateful and acknowledge to the authority of the respective departments and institutions for their support in carrying out this research. The authors also express their sincere gratitude to the unknown referee for critically reviewing the manuscript and suggesting useful changes. This research was funded by "Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI) del Gobierno de Canarias” (No. ProID2020010134), and o´Caja Canarias (Project No. 2019SP43).Peer reviewe